Regeneron, Sanofi Limit Kevzara Trial to Critical COVID-19 Patients

Sanofi and Regeneron have amended a phase 2/3 trial that is evaluating their arthritis drug Kevzara (sarilumab) for treatment of COVID-19 to enroll only critical patients.

The trial has been amended to include only patients requiring mechanical ventilation, high-flow oxygen or treatment in an intensive care unit. The patients will be given either a higher dose of Kevzara (400 mg) or placebo.

Preliminary analysis of phase 2 data identified negative trends for most outcomes in the severe group, but positive trends for all outcomes in the critical group.